Nanjing Vazyme Biotech Co.,Ltd

688105

CNE100004ZK3

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 28/05/2024 am IST			5-day change	1st Jan Change
22.95 ^CNY	-0.22%		-8.05%	-28.33%

26/04	Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
15/04	Nanjing Vazyme Biotech Unit Gets Nod to Register Six Medical Devices; Shares Slump 14%	MT

Nanjing Vazyme Biotech Co., Ltd. authorizes a Buyback Plan.

February 05, 2024

The Board of Directors of Nanjing Vazyme Biotech Co., Ltd. has authorized a buyback plan on February 5, 2024.

Latest news about Nanjing Vazyme Biotech Co.,Ltd

Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	27/04	CI
Nanjing Vazyme Biotech Unit Gets Nod to Register Six Medical Devices; Shares Slump 14%	15/04	MT
China stocks rise after new guidelines; HK shares drop	15/04	RE
Nanjing Vazyme Biotech Swings to Loss in 2023	29/02	MT
Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Nanjing Vazyme Biotech Co.,Ltd announces an Equity Buyback for CNY 160 million worth of its shares.	06/02	CI
Nanjing Vazyme Biotech Co., Ltd. authorizes a Buyback Plan.	05/02	CI
Tranche Update on Nanjing Vazyme Biotech Co.,Ltd's Equity Buyback Plan announced on August 22, 2023.	24/11	CI
Nanjing Vazyme Biotech Co.,Ltd's Equity Buyback announced on August 22, 2023, has closed with 618,077 shares, representing 0.15% for CNY 20.01 million.	24/11	CI
Certain A Shares of Nanjing Vazyme Biotech Co., Ltd. are subject to a Lock-Up Agreement Ending on 15-NOV-2023.	15/11	CI
Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Nanjing Vazyme Biotech Co.,Ltd(XSSC:688105) added to S&P Global BMI Index	18/23/18	CI
Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Nanjing Vazyme Biotech Plans Up to 30 Million Yuan Share Buyback	22/23/22	MT
Nanjing Vazyme Biotech Co.,Ltd announces an Equity Buyback for CNY 30 million worth of its shares.	22/23/22	CI
Nanjing Vazyme Biotech Co., Ltd. authorizes a Buyback Plan.	21/23/21	CI
Nanjing Vazyme Biotech Co., Ltd.(SHSE:688105) added to Shanghai Stock Exchange Health Care Sector Index	12/23/12	CI
Vazyme Biotech Registers New Pneumonia Pathogen Detection Kit	23/23/23	MT
Nanjing Vazyme Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Nanjing Vazyme Biotech Unit Gets Registration Certificate for Pneumonia-Detecting Kit	19/23/19	MT
Nanjing Vazyme Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI

Chart Nanjing Vazyme Biotech Co.,Ltd

Duration

Period

More charts

Nanjing Vazyme Biotech Co Ltd is China-based company principally engaged in biopharmaceuticals. The Company's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The Company's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.

Sector

Pharmaceuticals

Calendar

23/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Nanjing Vazyme Biotech Co.,Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.95 CNY

Average target price

35.72 CNY

Spread / Average Target

+55.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NANJING VAZYME BIOTECH CO.,LTD	-28.33%	1.26B
ELI LILLY AND COMPANY	+37.46%	727B
JOHNSON & JOHNSON	-7.84%	354B
MERCK & CO., INC.	+15.63%	328B
ABBVIE INC.	-0.47%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+3.91%	164B
PFIZER, INC.	-1.96%	164B

Other Pharmaceuticals